Vandria

Vandria Reports Positive Phase 1 Target Engagement Data for VNA-318, Supporting Further Development in Alzheimer’s Disease

Results presented at the 18th Clinical Trials in Alzheimer's Disease (CTAD) meeting, San Diego, December 1-4 VNA-318, an oral brain-penetrant small molecule therapeutic modulates a novel target to reduce inflammation and improve mitochondrial function First-in-human trial showed a highly favourable safety profile, with VNA-318 well tolerated across all dose levels without any safety concerns Single...
Route de la Corniche 8 1066 Epalinges Switzerland